Beta Drugs Limited

NSEI:BETA Rapport sur les actions

Capitalisation boursière : ₹20.6b

Beta Drugs Gestion

Gestion contrôle des critères 4/4

Le PDG Beta Drugs est Rahul Batra, nommé en Jan2021, a un mandat de 3.83 ans. La rémunération annuelle totale est ₹ 12.10M, composée du salaire de 100% et des bonus 0%, y compris les actions et options de la société. détient directement 0.41% des actions de la société, d'une valeur de ₹ 84.99M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 7.3 ans.

Informations clés

Rahul Batra

Directeur général

₹12.1m

Rémunération totale

Pourcentage du salaire du PDG100.0%
Durée du mandat du directeur général3.8yrs
Propriété du PDG0.4%
Durée moyenne d'occupation des postes de direction3.8yrs
Durée moyenne du mandat des membres du conseil d'administration7.3yrs

Mises à jour récentes de la gestion

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Analyse de la rémunération des PDG

Comment la rémunération de Rahul Batra a-t-elle évolué par rapport aux bénéfices de Beta Drugs?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

₹410m

Jun 30 2024n/an/a

₹387m

Mar 31 2024₹12m₹12m

₹364m

Dec 31 2023n/an/a

₹356m

Sep 30 2023n/an/a

₹348m

Jun 30 2023n/an/a

₹327m

Mar 31 2023₹12mn/a

₹307m

Dec 31 2022n/an/a

₹298m

Sep 30 2022n/an/a

₹289m

Jun 30 2022n/an/a

₹269m

Mar 31 2022₹8m₹8m

₹248m

Dec 31 2021n/an/a

₹216m

Sep 30 2021n/an/a

₹183m

Jun 30 2021n/an/a

₹150m

Mar 31 2021₹6m₹6m

₹117m

Dec 31 2020n/an/a

₹106m

Sep 30 2020n/an/a

₹95m

Jun 30 2020n/an/a

₹94m

Mar 31 2020₹5m₹5m

₹94m

Sep 30 2019n/an/a

₹97m

Jun 30 2019n/an/a

₹89m

Mar 31 2019₹1m₹1m

₹80m

Rémunération vs marché: La rémunération totale de Rahul ($USD 143.26K ) est dans la moyenne des entreprises de taille similaire sur le marché Indian ($USD 187.40K ).

Rémunération et revenus: La rémunération de Rahul a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Rahul Batra (41 yo)

3.8yrs

Titularisation

₹12,100,000

Compensation

Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Rahul Batra
Chairman & MD3.8yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director3.8yrs₹12.10m0.35%
₹ 71.2m
Nipun Arora
Chief Financial Officer3.7yrs₹3.10mpas de données
Rajni Brar
Company Secretary & Compliance Officer7.3yrs₹911.55kpas de données
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director5.7yrs₹5.12mpas de données
Seema Chopra
Whole Time Directorno data₹1.19mpas de données
Sanjeev Chopra
Vice President of Technicalno datapas de donnéespas de données

3.8yrs

Durée moyenne de l'emploi

40.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de BETA est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Rahul Batra
Chairman & MD10.3yrs₹12.10m0.41%
₹ 85.0m
Varun Batra
Joint MD & Whole Time Director10.3yrs₹12.10m0.35%
₹ 71.2m
Ashutosh Shukla
VP of Sales & Marketing and Whole Time Director2.8yrs₹5.12mpas de données
Seema Chopra
Whole Time Director5.3yrs₹1.19mpas de données
Manmohan Khanna
Independent Director7.3yrspas de donnéespas de données
Rohit Parti
Independent Director7.3yrspas de donnéespas de données

7.3yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BETA sont considérés comme expérimentés (ancienneté moyenne 7.3 ans).